CalciMedica, Inc. 8-K

What Happened
CalciMedica, Inc. announced on January 28, 2026 that it has discontinued the Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The decision followed a recommendation from the trial’s Independent Data Monitoring Committee (IDMC) after a prescheduled interim review identified a safety concern that the IDMC believes warrants reevaluation of the study design, particularly patient enrollment criteria. The company said it will perform a comprehensive review of the unblinded clinical data to assess impacts of baseline characteristics, disease severity, concomitant therapies and other factors.

Key Details

• Date of announcement: January 28, 2026.
• Trial: Phase 2 KOURAGE evaluating Auxora in Stage 2–3 AKI with AHRF; discontinued on IDMC recommendation.
• Safety: No deaths were assessed by investigators or the company as related to study drug (Auxora or placebo); no serious adverse events met FDA expedited-reporting criteria.
• Next steps: CalciMedica will review unblinded data, assess drivers of outcomes, notify and work with the FDA, and ensure currently enrolled patients complete the full 90-day follow-up.

Why It Matters
For investors, the discontinuation is material because it halts a late-stage clinical program for Auxora in AKI and triggers a company-led reanalysis that will determine whether and how the program can proceed. The outcome of the unblinded data review and any redesign or additional studies could affect timelines, development costs, regulatory interactions with the FDA, and the future clinical value of Auxora. The company has preserved follow-up of enrolled patients and is communicating with regulators, but further updates will be needed to understand potential impacts on CalciMedica’s development plans and finances.